Novartis investor calls for board overhaul after trial setbacks trigger record share fall
A leading shareholder in Novartis (NVS) has called for a shake-up of the Swiss drugmaker's board to strengthen corporate governance, after back-to-back clinical trial failures this week sent its shares to their steepest fall on record.
